Antiviral Inhibitors for Influenza and SARS-CoV-2 Treatment
Endosomal Acidification Inhibitors for Influenza Virus and Coronavirus Treatment
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology uses endosomal acidification inhibitors, such as chloroquine and P16 peptide, to inhibit viral replication in influenza viruses and SARS-CoV-2. The approach has demonstrated efficacy in animal models through intranasal administration, preventing viral replication without inducing drug-resistant variants. Applications include antiviral therapies targeting SARS-CoV-2 and influenza, addressing urgent healthcare needs during pandemics and seasonal outbreaks. The inhibitors showed safety with no significant hemolysis and effectiveness in reducing viral load in infected lung cells. Protected by US provisional patents, this innovation offers a novel antiviral strategy with broad applications in respiratory virus treatment.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Pharmaceutical Engineering; Biotechnology
